ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance

Core Insights - ICU Medical, Inc. reported a revenue of $540.7 million for Q4 2025, a decrease from $629.8 million in Q4 2024, indicating a year-over-year decline of approximately 14% [2] - The company experienced a GAAP net loss of $(15.7) million, or $(0.64) per diluted share, an improvement from a net loss of $(23.8) million, or $(0.97) per diluted share in the previous year [2][13] - Adjusted diluted earnings per share for Q4 2025 was $1.91, down from $2.11 in Q4 2024, while adjusted EBITDA was $98.2 million compared to $105.5 million in the same period last year [2][3] Financial Performance - Q4 2025 gross profit was $203.0 million, down from $227.3 million in Q4 2024, with a gross margin of 38%, up from 36% in the prior year [2][13] - For the full fiscal year 2025, total revenues were $2,231.3 million, a decrease from $2,382.0 million in 2024 [4] - The company’s fiscal year 2026 guidance estimates GAAP net income between $26 million to $44 million and adjusted EBITDA in the range of $400 million to $430 million [5] Product Line Performance - Revenue from consumables in Q4 2025 was $284.7 million, an increase of $16.6 million from $268.1 million in Q4 2024 [4] - Infusion systems revenue rose to $176.3 million, up by $4.6 million from $171.7 million in the same quarter last year [4] - Vital care revenue saw a significant decline, dropping to $79.7 million from $190.0 million in Q4 2024, reflecting a decrease of $110.3 million [4] Cash Flow and Balance Sheet - The company reported cash and cash equivalents of $307.963 million as of December 31, 2025, slightly down from $308.566 million a year earlier [10] - Total assets decreased to $4,050.508 million from $4,203.931 million in the previous year [11] - Current liabilities were reported at $498.861 million, down from $556.182 million in 2024 [11] Conference Call and Future Outlook - A conference call was scheduled to discuss the financial results, indicating the company's commitment to transparency and investor communication [6] - The company aims to provide quality and innovation in its medical products, focusing on growth in infusion systems and consumables [7]